
X4 Pharmaceuticals, Inc — Investor Relations & Filings
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-12 | English | |
| S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | |
| 10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | |
| ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | |
| DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | |
| DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45339551 | 8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-12 | English | ||
| 42006962 | S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | ||
| 41806531 | 10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | ||
| 32999251 | ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32999249 | DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32999239 | DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32963514 | 10-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-17 | English | ||
| 30181392 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181257 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181249 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181231 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 30181103 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 30181313 | SCHEDULE 13G/A Filing | 2026-02-05 | English | ||
| 30181211 | SCHEDULE 13G/A Filing | 2026-01-15 | English | ||
| 12390315 | FORM 4 | 2026-01-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AFC-HD AMS Life Science Co.,Ltd.
An OEM of health foods, supplements, and cosmetics with int…
|
2927 | JP | Manufacturing |
|
Afexa Life Sciences Inc.
Researched, developed, and manufactured naturally derived O…
|
FXA | CA | Manufacturing |
|
AFT Pharmaceuticals Limited
Develops, licenses, and distributes pharmaceuticals across …
|
AFT | NZ | Manufacturing |
|
AFT PHARMACEUTICALS LIMITED
Develops and licenses healthcare products for pain manageme…
|
AFP | AU | Manufacturing |
|
AGENUS INC
A clinical-stage biotechnology company specializing in immu…
|
AGEN | US | Manufacturing |
|
AGIOS PHARMACEUTICALS, INC.
Biopharmaceutical company developing therapies for rare and…
|
AGIO | US | Manufacturing |
|
AGP Limited
Pharmaceutical company manufacturing, marketing, and distri…
|
AGP | PK | Manufacturing |
|
AHN-GOOK PHARMACEUTICAL Co., Ltd.
Develops and markets medicines, focusing on respiratory and…
|
001540 | KR | Manufacturing |
|
AIM Vaccine Co., Ltd.
Develops, manufactures, and commercializes established and …
|
6660 | HK | Manufacturing |
|
AION THERAPEUTIC INC.
Health and wellness company developing AI-driven bio-pharma…
|
AION | CA | Manufacturing |
X4 Pharmaceuticals, Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34355/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34355 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34355 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34355 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34355}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for X4 Pharmaceuticals, Inc (id: 34355)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.